FDA testing found two undeclared medications in 10 Day Forecast, creating an unexpected nitrate-interaction risk and a hidden source of acetaminophen exposure.

The U.S. Food and Drug Administration is advising consumers not to purchase or use 10 Day Forecast, a product promoted for sexual enhancement, after laboratory testing identified two medications that were not disclosed on its label.

FDA announced the finding on October 15, 2026. Laboratory analysis confirmed that the product contains sildenafil and acetaminophen, creating two distinct medication-safety concerns: an unrecognized phosphodiesterase-5 inhibitor exposure that may interact dangerously with nitrates, and an unrecognized source of acetaminophen that can add to a consumer's total daily intake. [1]

FDA says 10 Day Forecast has been promoted and sold on various websites, including eBay, and may also be available in some retail stores. [1]

What FDA Testing Found

The laboratory finding is straightforward but clinically important:

Sildenafil — present but not listed on the label

Acetaminophen — present but not listed on the label

FDA has not disclosed how much of either ingredient is present in a capsule, serving or package. [1]

That means the findings establish hidden pharmaceutical exposure, but they do not allow clinicians or consumers to reconstruct the actual dose from the public notification.

The current FDA Sexual Enhancement and Energy Product Notifications page lists 10 Day Forecast as an October 15 Public Notification. [2]

The FDA materials reviewed for this article do not identify a separate voluntary or mandatory recall.

The correct regulatory description is therefore:

FDA public notification advising consumers not to purchase or use 10 Day Forecast.

Why Hidden Sildenafil Matters

Sildenafil is an approved prescription phosphodiesterase-5, or PDE-5, inhibitor with established therapeutic uses.

Its presence becomes a different safety problem when the consumer does not know it has been taken.

FDA specifically warns that sildenafil can interact with nitrate medications such as nitroglycerin and lower blood pressure to dangerous levels. [1]

Approved sildenafil labeling likewise lists use with organic nitrates or nitrites as contraindicated because sildenafil potentiates their hypotensive effects. [3]

The concern is therefore not that prescribed sildenafil is inherently unsafe.

The problem is unrecognized sildenafil exposure.

A patient may tell a clinician that they have not taken a PDE-5 inhibitor because none appears on the product label. That incomplete medication history can become clinically important when nitrate therapy is being considered for chest pain or another cardiovascular indication.

MedicalToxic previously documented the broader adulterated-product problem in FDA Finds Hidden Sildenafil and Tadalafil in Two Sexual-Enhancement Products, where FDA likewise identified undeclared PDE-5 inhibitors in products sold for sexual enhancement. FDA Finds Hidden Sildenafil and Tadalafil in Two Sexual-Enhancement Products

The 10 Day Forecast event adds a different concern because sildenafil is not the only hidden medication.

Hidden Acetaminophen Creates a Second Blind Spot

Acetaminophen is widely used for pain and fever and is generally safe when used appropriately.

But it is also present in many prescription and nonprescription medicines, which is why consumers are advised to know which products they take contain acetaminophen and to avoid unintentionally combining multiple acetaminophen-containing products. [4]

10 Day Forecast defeats that safeguard because its acetaminophen content is not disclosed on the label.

A consumer could therefore take 10 Day Forecast while also taking another medication containing acetaminophen without realizing that both products contribute to the same cumulative exposure.

FDA warns that excessive acetaminophen exposure can cause liver injury, ranging from abnormal liver function to acute liver failure and death. [1]

This does not mean ordinary use of 10 Day Forecast has been proven to deliver a hepatotoxic acetaminophen dose.

FDA has not published the acetaminophen concentration or amount per serving.

The defensible concern is narrower: the product introduces an unknown amount of acetaminophen into a medication history without telling the consumer or clinician.

Liver Injury May Not Be Immediately Obvious

The hidden acetaminophen is especially relevant because clinically important acetaminophen injury may not announce itself immediately.

FDA's notification cautions that symptoms may not appear for several days even when liver damage is severe, potentially delaying recognition and medical evaluation. [1]

That does not establish that 10 Day Forecast has caused liver injury.

It explains why an undisclosed acetaminophen exposure can complicate assessment: absence of obvious early symptoms does not necessarily reconstruct what the patient has actually ingested.

For emergency clinicians and poison centers, the relevant exposure history therefore extends beyond prescribed medications and explicitly labeled OTC products.

Sexual-enhancement products, supplements and internet-purchased preparations may contain pharmacologically active ingredients that are absent from the package label.

One Product, Two Different Medication-Reconciliation Problems

The unusual feature of this FDA finding is the combination.

Hidden sildenafil can conceal an interaction-relevant cardiovascular medication.

Hidden acetaminophen can conceal part of a patient's cumulative analgesic exposure.

Those are different toxicology pathways, but they share the same diagnostic problem: the label does not provide an accurate medication history.

A clinician treating hypotension, chest pain or another cardiovascular presentation may need to know whether a PDE-5 inhibitor has been taken.

A clinician evaluating possible acetaminophen exposure needs to know about all acetaminophen-containing products.

In 10 Day Forecast, FDA laboratory testing shows that neither exposure can be reliably identified from the product label alone. [1]

What FDA Has—and Has Not—Established

FDA has established that:

• 10 Day Forecast is promoted for sexual enhancement;

• FDA laboratory testing detected sildenafil;

• FDA laboratory testing detected acetaminophen;

• neither ingredient was listed on the product label; and

• FDA advises consumers not to purchase or use the product. [1]

FDA has not disclosed:

• the amount of sildenafil in the product;

• the amount of acetaminophen in the product;

• the number of people who used it;

• a product-specific incidence of hypotension or liver injury;

• a poisoning cluster;

• hospitalization or mortality counts attributed to the product; or

• a separate recall action.

The laboratory finding should therefore be described as confirmed hidden ingredient exposure, not confirmed clinical poisoning.

What Consumers Should Do

FDA advises consumers not to purchase or use 10 Day Forecast. [1]

People who have used the product should make that exposure known to healthcare professionals when medication history is relevant, particularly when cardiovascular treatment or acetaminophen-containing medicines are involved.

FDA also asks healthcare professionals and consumers to report suspected adverse events or side effects through the agency's MedWatch program. [1]

Consumers should not assume another sexual-enhancement product is safe simply because it does not appear on the current notification list.

FDA explicitly states that its notification list represents only a small fraction of contaminated sexual-enhancement products potentially on the market. [2]

What Is Genuinely New?

Hidden PDE-5 inhibitors in sexual-enhancement products are not new.

What makes the October 15 finding worth a dedicated product-specific News article is the combination of two undeclared medications with different clinical implications.

FDA found:

sildenafil → hidden interaction risk, particularly with nitrates

and

acetaminophen → hidden contribution to cumulative acetaminophen exposure

in the same product.

That creates a broader medication-reconciliation failure than a single undeclared erectile-dysfunction drug.

The consumer may not know either exposure occurred.

Limitations and Remaining Unknowns

The most important limitation is quantitative.

FDA has not published the sildenafil or acetaminophen concentration in 10 Day Forecast.

It is therefore inappropriate to infer that the sildenafil amount is equivalent to a standard prescription dose or to calculate a product-specific nitrate-interaction probability.

It is equally inappropriate to calculate an acetaminophen toxic dose or conclude that labeled product use produces hepatotoxic exposure.

The FDA notification also does not report product-specific adverse-event counts.

The evidence currently supports a precise conclusion:

10 Day Forecast contains two undeclared medications confirmed by FDA laboratory analysis, but their doses and the frequency of clinical harm among consumers are unknown.

Conclusion

FDA's October 15 warning about 10 Day Forecast highlights a particularly important form of adulterated-product risk.

The product contains undeclared sildenafil and undeclared acetaminophen. [1]

Sildenafil creates a potentially dangerous interaction with nitrate medications, while hidden acetaminophen can silently add to a consumer's total acetaminophen exposure.

Neither finding proves that users received a toxic dose or that the product caused a poisoning outbreak.

The clinical problem is more fundamental:

the consumer and clinician cannot reliably reconstruct the medication exposure from the label.

FDA currently advises consumers not to purchase or use 10 Day Forecast.

References

1. U.S. Food and Drug Administration. (2026, October 15).
10 Day Forecast may be harmful due to hidden ingredients

2. U.S. Food and Drug Administration. (2026).
Sexual Enhancement and Energy Product Notifications

3. DailyMed, U.S. National Library of Medicine.
Sildenafil Citrate Tablet, Film Coated — Prescribing Information

4. U.S. Food and Drug Administration. (2026).
Acetaminophen